The discovery of UK-369003, a novel PDE5 inhibitor with the potential for oral bioavailability and dose-proportional pharmacokinetics
Authors:
- David J. RawsonDRDavid J. Rawson
- Stephen BallardSBStephen Ballard
- Christopher BarberCBChristopher Barber
- Laura BarkerLBLaura Barker
- Kevin BeaumontKBKevin Beaumont
- Mark BunnageMBMark Bunnage
- Susan ColeSCSusan Cole
- Martin CorlessMCMartin Corless
- Stephen DentonSDStephen Denton
- David EllisDEDavid Ellis
- Marion Floc’hMFMarion Floc’h
- Laura FosterLFLaura Foster
- 1 January 2012
- journal article
- Published by Elsevier in Bioorganic & Medicinal Chemistry
- Vol. 20 (1) , 498-509
Abstract
No abstract availableKeywords
This publication has 14 references indexed in Scilit:
- A placebo‐controlled study investigating the efficacy and safety of the phosphodiesterase type 5 inhibitor UK‐369,003 for the treatment of men with lower urinary tract symptoms associated with clinical benign prostatic hyperplasiaBJU International, 2010
- PDE5 Inhibitors: In Vitro and In Vivo Pharmacological ProfileCurrent Pharmaceutical Design, 2009
- Phosphodiesterase-5 Inhibitors: Future PerspectivesCurrent Pharmaceutical Design, 2009
- Highly potent and selective chiral inhibitors of PDE5: An illustration of Pfeiffer’s ruleBioorganic & Medicinal Chemistry Letters, 2008
- A Novel Series of Potent and Selective PDE5 Inhibitors with Potential for High and Dose-Independent Oral BioavailabilityJournal of Medicinal Chemistry, 2006
- Structure of the catalytic domain of human phosphodiesterase 5 with bound drug moleculesNature, 2003
- Potential role for P-glycoprotein in the nonproportional pharmacokinetics of UK-343,664 in manXenobiotica, 2001
- Chapter 8. Pharmacological Therapy for the Treatment of Erectile Dysfunction1999
- EFFECTS OF SILDENAFIL ON THE RELAXATION OF HUMAN CORPUS CAVERNOSUM TISSUE IN VITRO AND ON THE ACTIVITIES OF CYCLIC NUCLEOTIDE PHOSPHODIESTERASE ISOZYMESJournal of Urology, 1998
- A novel proline derived meso-ionic synthonTetrahedron Letters, 1983